NO882469L - Fremgangsmaate for produksjon av proteiner ved bruk av induserbare ekspresjonssystemer i genetisk modifiserte eukaryote vertsceller formert in vivo. - Google Patents
Fremgangsmaate for produksjon av proteiner ved bruk av induserbare ekspresjonssystemer i genetisk modifiserte eukaryote vertsceller formert in vivo.Info
- Publication number
- NO882469L NO882469L NO882469A NO882469A NO882469L NO 882469 L NO882469 L NO 882469L NO 882469 A NO882469 A NO 882469A NO 882469 A NO882469 A NO 882469A NO 882469 L NO882469 L NO 882469L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- gene
- plasmid
- tumor
- promoter
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 21
- 230000014509 gene expression Effects 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 37
- 241000206602 Eukaryota Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 80
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 119
- 239000002609 medium Substances 0.000 claims description 40
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 33
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 28
- 239000000854 Human Growth Hormone Substances 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 27
- 210000004881 tumor cell Anatomy 0.000 claims description 27
- 241000699670 Mus sp. Species 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 15
- 239000012679 serum free medium Substances 0.000 claims description 15
- 238000011654 sencar mouse Methods 0.000 claims description 14
- 230000035939 shock Effects 0.000 claims description 13
- 229930193140 Neomycin Natural products 0.000 claims description 12
- 108700020796 Oncogene Proteins 0.000 claims description 12
- 229960004927 neomycin Drugs 0.000 claims description 12
- 241000701822 Bovine papillomavirus Species 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 238000011081 inoculation Methods 0.000 claims description 11
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 claims description 10
- 101150031823 HSP70 gene Proteins 0.000 claims description 10
- 101150052825 dnaK gene Proteins 0.000 claims description 10
- 101150074155 DHFR gene Proteins 0.000 claims description 9
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 4
- 238000012761 co-transfection Methods 0.000 claims description 4
- 102000043276 Oncogene Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 2
- 108020004440 Thymidine kinase Proteins 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 230000009466 transformation Effects 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 1
- 238000005227 gel permeation chromatography Methods 0.000 claims 1
- 239000012510 hollow fiber Substances 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000011580 nude mouse model Methods 0.000 description 42
- 241000699660 Mus musculus Species 0.000 description 33
- 238000007920 subcutaneous administration Methods 0.000 description 20
- 241000700159 Rattus Species 0.000 description 17
- 238000002054 transplantation Methods 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 10
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 239000012894 fetal calf serum Substances 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920004011 Macrolon® Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP86810455A EP0263908B1 (en) | 1986-10-15 | 1986-10-15 | Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo |
| PCT/EP1987/000599 WO1988002778A1 (en) | 1986-10-15 | 1987-10-12 | Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO882469D0 NO882469D0 (no) | 1988-06-03 |
| NO882469L true NO882469L (no) | 1988-06-03 |
Family
ID=8196470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO882469A NO882469L (no) | 1986-10-15 | 1988-06-03 | Fremgangsmaate for produksjon av proteiner ved bruk av induserbare ekspresjonssystemer i genetisk modifiserte eukaryote vertsceller formert in vivo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5614381A (enExample) |
| EP (2) | EP0263908B1 (enExample) |
| JP (1) | JP2509271B2 (enExample) |
| AT (1) | ATE67787T1 (enExample) |
| AU (1) | AU612607B2 (enExample) |
| CA (1) | CA1319631C (enExample) |
| DE (1) | DE3681738D1 (enExample) |
| DK (1) | DK320888D0 (enExample) |
| ES (1) | ES2038602T3 (enExample) |
| NO (1) | NO882469L (enExample) |
| WO (1) | WO1988002778A1 (enExample) |
| ZA (1) | ZA877656B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85728A (en) * | 1987-03-25 | 1993-01-14 | Bio Mega Inc | Fluorine containing atrial natriuretic peptides, their preparation and pharmaceutical compositions containing them |
| JP2796547B2 (ja) * | 1987-09-11 | 1998-09-10 | ジェネンテク，インコーポレイテッド | 組換え細胞培養中でのポリペプチド発現の増大法 |
| EP0390857A4 (en) * | 1987-12-15 | 1991-04-17 | The Trustees Of Princeton University | Transgenic testing systems for mutagens and carcinogens |
| ZA892518B (en) * | 1988-04-08 | 1989-12-27 | Intracel Corp | Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells |
| WO1990001543A1 (fr) * | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| GB8928884D0 (en) * | 1989-12-21 | 1990-02-28 | Feldmann Marc | Transformed cell lines |
| GB9003791D0 (en) * | 1990-02-20 | 1990-04-18 | Ludwig Inst Cancer Res | Transgenic animals,cell lines therefrom,and their use |
| US5866759A (en) * | 1991-02-20 | 1999-02-02 | Ludwig Institute For Cancer Research | Transgenic mice expressing TSSV40 large T antigen |
| US5877398A (en) * | 1993-01-29 | 1999-03-02 | University Of British Columbia | Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology |
| JP2001501458A (ja) | 1996-08-15 | 2001-02-06 | アメリカ合衆国 | ヒートショックタンパク質プロモーターと局部加熱との組合せを利用した遺伝子発現の場所的及び時期的制御 |
| IT1294450B1 (it) * | 1997-08-28 | 1999-03-25 | Consiglio Nazionale Ricerche | Animali transgenici per lo studio di agenti tossici chimici fisici o biologici |
| US7098191B2 (en) * | 1997-11-03 | 2006-08-29 | The Arizona Board Of Reagents | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| US6709858B1 (en) * | 1997-11-03 | 2004-03-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| US7279565B2 (en) * | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| AUPQ233799A0 (en) | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
| US20030044398A1 (en) * | 2001-03-20 | 2003-03-06 | Robl James M. | Methods for producing antibodies in mammals |
| CA2349506C (en) * | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| WO2006037215A1 (en) * | 2004-10-04 | 2006-04-13 | National Research Council Of Canada | Expression system, components thereof and methods of use |
| US7935788B2 (en) * | 2004-10-04 | 2011-05-03 | National Research Council Of Canada | Reverse cumate repressor mutant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| JPS5729294A (en) * | 1980-07-30 | 1982-02-17 | Hayashibara Biochem Lab Inc | Preparation of human insulin |
| JPS5852634B2 (ja) * | 1980-12-05 | 1983-11-24 | 株式会社林原生物化学研究所 | ウロキナ−ゼの製造法 |
| IE56720B1 (en) * | 1983-02-07 | 1991-11-20 | Battelle Memorial Institute | Methods and compositions for expression of competent eukaryotic gene products |
| WO1987005935A1 (en) * | 1986-04-04 | 1987-10-08 | Battelle Memorial Institute At Columbus, Ohio Gene | Methods and compositions for expression of competent eukaryotic gene products |
| AU8108687A (en) * | 1986-09-30 | 1988-04-21 | Smithkline Beckman Corporation | Cell transfection |
| PT87363B (pt) * | 1987-05-01 | 1993-11-30 | Gen Hospital Corp | Metodo para alterar a concentracao de um produto genetico |
-
1986
- 1986-10-15 DE DE86810455T patent/DE3681738D1/de not_active Expired - Lifetime
- 1986-10-15 ES ES198686810455T patent/ES2038602T3/es not_active Expired - Lifetime
- 1986-10-15 AT AT86810455T patent/ATE67787T1/de not_active IP Right Cessation
- 1986-10-15 EP EP86810455A patent/EP0263908B1/en not_active Expired - Lifetime
-
1987
- 1987-10-12 EP EP87906742A patent/EP0285642A1/en not_active Withdrawn
- 1987-10-12 AU AU80784/87A patent/AU612607B2/en not_active Ceased
- 1987-10-12 WO PCT/EP1987/000599 patent/WO1988002778A1/en not_active Ceased
- 1987-10-12 JP JP62506060A patent/JP2509271B2/ja not_active Expired - Lifetime
- 1987-10-12 ZA ZA877656A patent/ZA877656B/xx unknown
- 1987-10-14 CA CA000549217A patent/CA1319631C/en not_active Expired - Fee Related
-
1988
- 1988-06-03 NO NO882469A patent/NO882469L/no unknown
- 1988-06-13 DK DK320888A patent/DK320888D0/da not_active Application Discontinuation
-
1995
- 1995-04-13 US US08/421,277 patent/US5614381A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1988002778A1 (en) | 1988-04-21 |
| US5614381A (en) | 1997-03-25 |
| AU612607B2 (en) | 1991-07-18 |
| DE3681738D1 (enExample) | 1991-10-31 |
| EP0263908B1 (en) | 1991-09-25 |
| EP0263908A1 (en) | 1988-04-20 |
| NO882469D0 (no) | 1988-06-03 |
| JP2509271B2 (ja) | 1996-06-19 |
| ATE67787T1 (de) | 1991-10-15 |
| DK320888A (da) | 1988-06-13 |
| AU8078487A (en) | 1988-05-06 |
| EP0285642A1 (en) | 1988-10-12 |
| JPH01501439A (ja) | 1989-05-25 |
| ES2038602T3 (es) | 1993-08-01 |
| ZA877656B (en) | 1988-04-18 |
| DK320888D0 (da) | 1988-06-13 |
| CA1319631C (en) | 1993-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO882469L (no) | Fremgangsmaate for produksjon av proteiner ved bruk av induserbare ekspresjonssystemer i genetisk modifiserte eukaryote vertsceller formert in vivo. | |
| Slack et al. | Regulation of expression of the type I collagen genes | |
| Zelcer et al. | Culture of newly isolated tobacco protoplasts: precursor incorporation into protein, RNA and DNA | |
| Foster et al. | Positive and negative cis-acting regulatory elements mediate expression of the mouse vascular smooth muscle alpha-actin gene. | |
| CN106636210B (zh) | 转录因子组合诱导成纤维细胞转分化为类睾丸间质细胞的方法 | |
| CN101792732A (zh) | 人多能干细胞生长和分化的技术 | |
| JP2003506076A5 (enExample) | ||
| US5861278A (en) | HNF3δ compositions | |
| EP0485689B1 (en) | Cells growing in protein-free medium, and enhancing replication of exogenous genes | |
| Frazier et al. | Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3 | |
| LU507631B1 (en) | Crispr/cas9-grna targeting plasmid, donor plasmid, and preparation method for immortalized mouse cell line | |
| Tomei et al. | Phorbol ester and Epstein—Barr virus dependent transformation of normal primary human skin epithelial cells | |
| CN102876700B (zh) | PiggyBac转座子介导的肌肉特异表达A-FABP通用载体构建 | |
| Ramsay et al. | Neoplastic transformation and tumorigenesis by the human protooncogene MYC. | |
| CN109055379A (zh) | 一种转基因鸡输卵管生物反应器的制备方法 | |
| CN102154288B (zh) | 一种骨骼肌特异性capn3启动子及其应用 | |
| Asselin et al. | Mutation in the polyomavirus genome that activates the properties of large T associated with neoplastic transformation | |
| AU600481B2 (en) | Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same | |
| TWI245048B (en) | Methods and constructs for protein expression | |
| Muhitch et al. | Characterization of aggregation and protein expression of bovine corneal endothelial cells as microcarrier cultures in a rotating-wall vessel | |
| Dreano et al. | Production of secretable proteins using the passage in vivo as tumours of cells carrying heat-inducible expression constructs | |
| CN116948975A (zh) | Ifnar1基因敲除的mdck细胞株及其构建方法和应用 | |
| Okker-Reitsma et al. | Isolation and culture of smooth muscle cells from human umbilical cord arteries | |
| CN115161342A (zh) | 一种具有新遗传性状的细胞系和动物的构建方法 | |
| CN112608947A (zh) | 一种永生化人皮脂腺细胞系的构建方法及其应用 |